Kamata Yoshinori, Sato Hiroshi, Joh Kensuke, Tsuchiya Yoshinori, Kunugi Shinobu, Shimizu Akira, Konta Tsuneo, Baughman Robert P, Azuma Arata
Kitamurayama Hospital, Higashine, Japan.
Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):252-260. doi: 10.36141/svdld.v35i3.6655. Epub 2018 Apr 28.
Although some articles have described renal sarcoidosis, the incidence among biopsy cases remains unclear. Here, we defined the incidence of renal sarcoidosis among renal biopsy cases and analyzed the clinical course. We performed an epidemiological study examining renal biopsy cases treated at 5 centers between January 2000 and September 2015 and identified 16 cases (7 men, 9 women; mean (±SD) age, 59.4±18.6 years) out of a total of 14191 renal biopsy cases. Renal involvement of sarcoidosis was defined as granulomatous tubulointerstitial nephritis, tubulointerstitial nephritis without granulomatous lesions, and renal calcinosis. Fifteen of the cases were treated with steroid therapy. One case initially received steroid pulse therapy. The outcome was evaluated based on the estimated glomerular filtration rate (eGFR), CKD stage, and the change in eGFR (ΔeGFR) after treatment. A favorable response was defined as ΔeGFR ≥25%. The incidence of renal sarcoidosis was 0.11%. The mean eGFR was 28.2±16.1 mL/min/1.73 m. At the last observation, the mean eGFR was 43.7±19.7 mL/min/1.73 m. Although a favorable response to steroid therapy was found in the majority of cases (10/15, 67%), 12 of the 15 cases (80%) had residual renal dysfunction at the last observation and 8 cases (53%) had moderate to severe renal dysfunction. Renal sarcoidosis is extremely rare among renal biopsy cases. Among cases with an unfavorable response to steroid therapy, pathogenetic mechanisms other than sarcoidosis and severe nephron damage were observed. .
虽然已有一些文章描述了肾结节病,但活检病例中的发病率仍不明确。在此,我们确定了肾活检病例中肾结节病的发病率,并分析了其临床病程。我们进行了一项流行病学研究,调查了2000年1月至2015年9月期间在5个中心接受治疗的肾活检病例,在总共14191例肾活检病例中识别出16例(7例男性,9例女性;平均(±标准差)年龄为59.4±18.6岁)。结节病的肾脏受累定义为肉芽肿性肾小管间质性肾炎、无肉芽肿病变的肾小管间质性肾炎和肾钙质沉着症。其中15例接受了类固醇治疗。1例最初接受了类固醇冲击治疗。根据估计的肾小球滤过率(eGFR)、慢性肾脏病(CKD)分期以及治疗后eGFR的变化(ΔeGFR)对结果进行评估。良好反应定义为ΔeGFR≥25%。肾结节病的发病率为0.11%。平均eGFR为28.2±16.1 mL/min/1.73 m²。在最后一次观察时,平均eGFR为43.7±19.7 mL/min/1.73 m²。虽然大多数病例(10/15,67%)对类固醇治疗有良好反应,但在最后一次观察时,15例中的12例(80%)仍有残余肾功能不全,8例(53%)有中度至重度肾功能不全。肾结节病在肾活检病例中极为罕见。在对类固醇治疗反应不佳的病例中,观察到了结节病以外的发病机制和严重的肾单位损伤。